Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

K Schumann, C Mauch, KC Klespe, C Loquai, U Nikfarjam, M Schlaak, L Akcetin, P Kolblinger (Co-author), M Hoellwerth (Co-author), M Meissner, G Mengi, AD Braun, M Mengoni, R Dummer, J Mangana, MA Sindrilaru, D Radmann, C Hafner, J Freund, K RappersbergerF Weihsengruber, F Meiss, L Reinhardt, F Meier, B Rainer, E Richtig, JM Ressler, C Holler, T Eigentler, T Amaral, WK Peitsch, U Hillen, W Harth, F Ziller, K Schatton, T Gambichler, L Susok, LV Maul, H Laubli, Dirk Debus (Co-author), C Weishaupt, S Borger, K Sievers, S Haferkamp, V Zenderowski, V Nguyen, M Wanner, R Gutzmer, P Terheyden, K Kahler, S Emmert, A Thiem, M Sachse, S Gercken-Riedel, KM Kaune, KM Thoms, L Heinzerling, MV Heppt, S Tratzmiller, W Hoetzenecker, A Ollinger, A Steiner, T Peinhaupt, M Podda, S Schmid, U Wollina, T Biedermann, C Posch

Research output: Contribution to journalOriginal Articlepeer-review

17 Citations (Web of Science)
Original languageEnglish
Pages (from-to)894-906
Number of pages13
JournalJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume37
Issue number5
Early online date12 Dec 2022
DOIs
Publication statusPublished - May 2023

Keywords

  • STAGE-III
  • MULTICENTER
  • IPILIMUMAB
  • NIVOLUMAB
  • Melanoma/pathology
  • Melanoma, Cutaneous Malignant
  • Humans
  • Proto-Oncogene Proteins B-raf/genetics
  • Mitogen-Activated Protein Kinase Kinases/therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Switzerland
  • Skin Neoplasms/pathology
  • Austria
  • Adjuvants, Immunologic/therapeutic use
  • Retrospective Studies

Cite this